Why the Exact Lymphoma Diagnosis Must Be Settled First
Diffuse large B-cell lymphoma is not a single uniform disease. The NCI notes that lymphoma includes Hodgkin and non-Hodgkin types, and that the exact diagnosis matters when discussing treatment. For DLBCL, that means the pathology report should identify the subtype and any relevant biomarker results the treating team relies on. Without that, an MDT discussion is working from an incomplete picture.
Before any discussion in China, ask whether the original biopsy slides and the full pathology report can be reviewed. If the diagnosis was made elsewhere, a pathology re-review may be requested. This is not a routine step for every patient, but it is a question the receiving team should answer: do they need the slides, the blocks, or both, and will they accept the existing report as sufficient?
The practical consequence is straightforward. If the subtype or biomarker status is unclear, the MDT cannot meaningfully compare treatment options. Ask what specific pathology or molecular information is missing and whether it changes the recommendation.
What Prior Treatment History the MDT Actually Needs
For a patient with relapsed or refractory DLBCL, the MDT needs a clear timeline of every prior regimen: which drugs were used, how many cycles were completed, what the response was, and why treatment changed. A summary letter is not enough if it omits response assessments or dates.
Ask the hospital what format they want for this history. Some teams prefer a structured chronology; others want the original imaging reports and discharge summaries. The key question is whether the MDT can reconstruct the treatment course from the records you provide, or whether gaps remain.
If the patient is currently on treatment, do not interrupt it for an overseas enquiry. The MDT discussion is a planning step, not a reason to pause care. Ask whether the team can review records while treatment continues locally.
Relapsed Disease: What the Discussion Should Clarify
Relapsed DLBCL raises specific questions that a general lymphoma discussion may not address. The MDT should clarify whether the disease is truly refractory or has relapsed after a response, what the prior response duration was, and whether the patient is a candidate for further systemic therapy, targeted approaches, or cellular therapy assessment.
This is not a treatment recommendation. It is a question of what the team can assess from records. Ask explicitly: based on the records provided, what options are being considered, and what additional information would change that assessment?
If the discussion touches on clinical trials, transplantation, or cellular therapy, remember that a records-based review does not establish eligibility. Those are separate determinations made by the treating team after full assessment. Ask what the next step would be if the patient travelled, and what cannot be confirmed remotely.
What an MDT Discussion Cannot Guarantee
A hospital may not offer a formal multidisciplinary meeting for every patient. Some centres hold regular tumour boards; others coordinate opinions informally between specialists. You cannot assume that a request for an MDT will be met with a scheduled meeting.
Ask directly: does this hospital hold a formal MDT for lymphoma, how often, and who participates? If the answer is that opinions are gathered individually, ask how that differs from a coordinated discussion and whether the patient receives a single consolidated recommendation.
A remote review also cannot confirm hospital acceptance, treatment availability, or a final plan. It is a records-based opinion. The treating team in China decides suitability after seeing the patient and any additional tests they require.
How to Prepare Records for a Useful Discussion
The quality of an MDT discussion depends on the records provided. A brief summary is enough for an initial enquiry, but a substantive review needs more. Ask the hospital what they require before you send a complete archive, and ask them to name the specific documents rather than a general category. "Pathology and imaging" can mean different things to different departments, and sending the wrong version wastes a review cycle.
For a DLBCL case, the pathology report is the anchor document. It should state the subtype and any biomarker results the treating team relies on. If the original biopsy was read elsewhere, ask whether the receiving pathologist wants to review the slides, the blocks, or both, and whether the existing report is accepted as sufficient. That answer determines whether a pathology re-review is part of the plan or not.
The treatment chronology matters as much as the diagnosis. Build a table with one row per regimen: drug names, start and end dates, number of cycles completed, the response assessment after that regimen, and the reason treatment changed. If a regimen was stopped early, note why. If response was assessed by imaging, include the report date and the conclusion, not just the scan date. An MDT cannot compare options if the prior response is described only as "good" or "partial" without the underlying assessment.
Imaging should be sent in a usable form. Ask whether the hospital wants the written reports, the discs, or both, and whether they can read the disc format used by your imaging centre. A report without images may be enough for orientation but not for a detailed review. Confirm this before shipping discs internationally, because the format question is easier to resolve before the files leave your country.
Recent blood tests, biomarker or molecular reports, and any discharge summaries from hospital admissions should accompany the core documents. If the patient has had a recent infection, hospitalisation, or a change in organ function, include those records too, because they can affect what the team considers feasible. Do not send passport numbers, card details, or payment information in an initial enquiry; those belong to a later administrative stage, not a clinical review.
Language is a practical bottleneck. If records are in another language, ask whether the hospital requires a translation, who arranges it, and whether a summary translation is acceptable or a full certified translation is needed. Do not assume that English reports are accepted without question, and do not pay for translation before confirming the hospital's preference. A short email asking "what do you need, in what language, and in what format" prevents most of this waste.
Finally, write down your own questions before you send anything. A records review answers the questions it is asked. If you want to know whether the prior regimen was adequate, whether a specific option is available, or what the next step would be after travel, state those questions explicitly in the covering note. The MDT can then address them directly rather than producing a general summary that leaves the real decision unresolved.
- Pathology report and, if requested, slides or blocks
- Imaging reports and discs, especially the most recent PET or CT
- Treatment chronology with drug names, dates, cycles, and response
- Recent blood tests and any biomarker or molecular reports
- A written list of your specific questions for the team
Questions to Ask Before You Commit to Travel
Before travelling to China for DLBCL care, ask the hospital or coordinating team a short set of questions. These are administrative and clinical-boundary questions, not a request for a treatment plan.
First, will the hospital review records remotely, and what is the scope of that review? Second, does the hospital hold a formal MDT for lymphoma, and will the patient receive a written summary of the discussion? Third, what additional tests or consultations would be required in person before a final plan is made?
Fourth, what is the expected sequence of appointments, and who is responsible for coordinating them? Fifth, what costs are covered by any quoted coordination fee, and what is paid directly to the hospital? Ask for this in writing.
Finally, if the patient is currently receiving treatment, ask whether the team recommends completing current cycles before travel. Do not stop or delay local care based on an overseas enquiry.
ChinaSpecialistCare can help with an initial records review and, where appropriate, arrange a multidisciplinary review involving relevant specialties. The scope and fee are agreed first. An initial enquiry is free and does not require buying a proxy consultation. The hospital decides suitability.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.